Cuidado em enfermagem de reabilitação e processo emancipatório

Background: e science of nursing is immersed in the process of care, and, historically speaking, the profession was built based on scientific criteria of what care is and how to practice it. is study explores how to practice nursing care as an emancipatory process. Objective: is article aims to share and stimulate the debate about nursing care and emancipatory process, using Honneth’s theory of recognition and Bloch’s principle of hope. Main topics under analysis: Reflection on the theory of recognition and principle of hope as conceptual foundations for rehabilitation nursing care. Study based on philosophical literature about rehabilitation. Nursing care is considered an intersubjective relationship in the emancipatory process, in which the self-realization of the nurse depends on the self-realization of the cared-for person. Conclusion: e construction of the subject occurs in intersubjective, historical, and recognition relationships. For responsible care, we should consider the three levels of recognition: love, rights, and solidarity. In this sense, the care will be an integral and emancipatory process.Enquadramento: A ciência da enfermagem está imersa no processo de cuidar, e, historicamente, a profissão foi construída com base em critérios científicos sobre o que é e como cuidar. Este estudo pretende questionar como se pratica o cuidado de enfermagem enquanto processo emancipatório. Objectives: Este artigo tem como objetivo compartilhar e estimular o debate sobre cuidados de enfermagem e processo empancipatório, usando a teoria do reconhecimento de Honneth e o princípio da esperança de Bloch. Principais tópicos em análise: Reflexão sobre a teoria do reconhecimento e dialética da esperança como fundamentos conceituais para o cuidado de enfermagem na reabilitação. Baseado na literatura filosófica contextualizada na reabilitação. Para isso, o cuidado de enfermagem é considerado uma relação intersubjetiva num processo emancipatório, no qual a autorrealização do enfermeiro depende da autorrealização da pessoa cuidada. Conclusão: A construção do sujeito ocorre em relações intersubjetivas, históricas e de reconhecimento. Para o cuidado responsável, devemos considerar os três níveis de reconhecimento: amor, direitos e solidariedade. Assim, o cuidado será um processo emancipatório e integral.info:eu-repo/semantics/publishedVersio

Trocador de calor e umidade: proteção contra infecções pulmonares? Estudo piloto

O objetivo deste trabalho foi realizar um estudo bacteriológico comparativo entre os sistemas de umidificação aquoso aquecido (UAA) e filtro trocador de calor e umidade (FTCU) quanto à colonização bacteriana e a incidência de infecção respiratória em pacientes submetidos à ventilação mecânica (VM). Trata-se de uma pesquisa prospectiva, controlada e randomizada, na qual 15 pacientes internados na Unidade de Terapia Intensiva (UTI) foram distribuídos em dois grupos. O primeiro fez uso de UAA (n=7) e o outro de FTCU (n=8). Foram coletadas amostras da secreção traqueal, condensado do circuito e FTCU na admissão do paciente, no quarto e oitavo dias, e realizada análise bacteriológica dos mesmos. Quanto às características antropométricas, não observou-se diferenças entre os grupos estudados. A prevalência de pneumonia associada à ventilação (PAV) foi de 57,1% no UAA e 62,5% no FTCU. Ao realizar a análise bacteriológica quantitativa entre eles, não foram observadas variações, sugerindo não haver diferença na prevenção de PAV entre os sistemas de umidificação; porém a presença das mesmas bactérias na secreção traqueal e no condensado e ausência destas na membrana do FTCU podem indicar que a principal fonte de contaminação é o próprio paciente.The aim of this study was to conduct a bacteriological research comparing the aqueous heated humidification systems (HH) and filter heat and moisture exchanger (FHME) and to bacterial colonization and the incidence of respiratory infection in patients undergoing mechanical ventilation. It is a prospective, controlled trial, in that 15 intensive care unit (ICU) patients were divided into two groups. The first made use of HH (n=7) and the other, FHME (n=8). We collected samples of tracheal secretions, and condensate circuit FHME at admission in the fourth and eighth day and bacteriological analysis of the same place. Regarding the anthropometric characteristics, no differences were observed between the groups. The prevalence of ventilator associated pneumonia (VAP) was 57.1% in the HH and 62.5% in FHME. When performing quantitative bacteriological analysis between the group and HH and FHME, differences were not observed, suggesting no variation in the prevention of VAP between the humidification systems, but the presence of these bacteria in the tracheal and condensate and in the absence of these membrane FHME may indicate that the main source of contamination is the patient himself

COVID-19 in Brazilian children and adolescents: findings from 21 hospitals / COVID-19 em crianças e adolescentes brasileiros: registros de 21 hospitais

Introdução: Crianças e adolescentes com Covid-19 apresentam menor mortalidade e sintomas menos intensos quando comparados aos adultos. Os estudos no Brasil baseiam-se apenas no sistema de notificação compulsória. Objetivo: Analisar as características clínicas, laboratoriais, radiológicas e desfechos de pacientes hospitalizados com menos de 20 anos de idade com Covid-19. Métodos: Série de casos de pacientes internados com Covid-19, confirmado, com idade inferior a 20 anos, obtida em estudo de coorte em 21 hospitais de cinco estados brasileiros. Resultados: Dos 36 pacientes, 20 (55,5%) eram adolescentes, 20 (55,5%) eram do sexo masculino, 18 (50,0%) apresentavam comorbidades, 2 estavam grávidas; e em 7 (19,4%) os sintomas iniciais ocorreram durante a internação por outras causas, dos quais 3 foram possivelmente infectados no hospital. Febre (61,1%), dispneia (33,3%) e sintomas neurológicos (33,0%) foram as queixas mais comuns. A proteína C reativa estava acima de 50mg / L em 16,7% e o dímero-D estava acima do limite de referência em 22,2%. Radiografias de tórax foram realizadas em 20 (55,5%) pacientes, 9 apresentavam anormalidades; e tomografias computadorizadas de tórax em 5. O tempo de internação variou de 1-40 dias (mediana 5 [intervalo interquartil 3-10]), 16 (44,4%) necessitaram de cuidados intensivos, 6 (16,7%) necessitaram de ventilação mecânica e um paciente (2,8%) faleceu. Conclusão: Em uma amostra de pacientes menores de 20 anos, procedentes de hospitais de 5 estados do Brasil, as comorbidades foram frequentes e os sintomas mais comuns foram febre, dispneia e sintomas neurológicos. Quarenta e quatro por cento dos pacientes necessitaram de cuidados intensivos, mostrando que na amostra avaliada a doença não era tão leve quanto o esperado, e um paciente morreu. 

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Synthesis, vasodilator activity and toxicity of new derivative pirazólico (LQFM 021), a possible inhibitor of phosphodiesterase

Made available in DSpace on 2014-07-29T16:11:50Z (GMT). No. of bitstreams: 1 Dissertacao DAniella Ramos Martins.pdf: 914272 bytes, checksum: 038f97a7fcd95721aab346f4a3bd0587 (MD5) Previous issue date: 2012-02-28The inhibition of phosphodiesterases (PDEs) increases intracellular levels of cyclic nucleotides 3 ': 5'-cyclic adenosine monophosphate (cAMP) and 3 ': 5'-cyclic guanosine monophosphate (cGMP), which has many physiological and biochemical effects, especially in cardiovascular system. The objective of this study was to analyze the pharmacological effects of a new compound derived from pyrazole, LQFM 021, which was indicated by molecular modeling studies as a possible inhibitor of PDE-3. For this purpose, aortas were isolated of rats and mounted in organ baths for isometric tension recording of the relaxing effect of LQFM 021, in preparations pre-contracted with phenylephrine. We analyzed the involvement of the vascular endothelium, soluble guanylate cyclase (sGC) and adenylate cyclase (AC), the role of K+ channels and Ca2+, besides the contribution of Ca2+ uptake by the sarcoplasmic reticulum. As a result, was demonstrated that the LQFM 021 induces vascular relaxation (Emax: 54.9 ± 6.0%), being this relaxation potentiated by endothelium (Emax: 88.1 ± 2.1%). The inhibition of AC with MDL-12.330A (10 μM) or of the sGC with ODQ (1 μM) reduced the relaxation of 88.1 ± 2.1%, to 48.35 ± 3.01% and 19.95 ± 2.32%, respectively. The pre-contraction with KCl 45 mM or treatment of preparations with TEA (5 mM), reduced almost completely the relaxing effect of the compound. Inhibition of Ca2+ / ATPase reticular with CPA (10 mM) reduced the relaxation stimulated by 021 LQFM approximately 66.5%. Concentration-response curve contractile induced by phenylephrine (0.1 nM to 1 μM) or by CaCl2 (0-3 mM, zero-calcium + phenylephrine) were reduced by pretreatment of preparations with LQFM 021 (EC50). In conclusion, this study showed that the new synthetic derivative of pyrazole LQFM 021 is a potential inhibitor of PDE-3 and has vasorelaxant activity. The endothelium potentiates the relaxation stimulated by the compound. The route of sGC and AC are involved in the mechanism of action of LQFM 021. Was also evidenced by participation from sarcoplasmatic reticulum, well as the flow of K+ and Ca2+ through the cell membrane.A inibição das fosfodiesterases (PDEs) aumenta os níveis intracelulares de nucleotídeos cíclicos 3' : 5'-monofosfato cíclico de adenosina (AMPc) e 3' : 5'-monofosfato cíclico de guanosina (GMPc), os quais tem muitos efeitos fisiológicos e bioquímicos, sobretudo no sistema cardiovascular. O objetivo deste estudo foi analisar os efeitos farmacológicos de um novo composto derivado do pirazol, LQFM 021, o qual foi apontado por estudos de modelagem molecular como possível inibidor de PDE-3. Para tanto, artérias aortas de ratos foram isoladas e montadas em banhos de órgão para registro da tensão isométrica do efeito relaxante do LQFM 021, em preparações pré-contraídas com fenilefrina. Foi analisada a participação do endotélio vascular, da guanilato ciclase solúvel (GCs) e da adenilato ciclase (AC), o papel dos canais de K+ e de Ca2+, além da contribuição da captação de Ca2+ pelo retículo sarcoplasmático. Como resultado, foi demonstrado que o LQFM 021 induz relaxamento vascular (Emax: 54.9 ± 6.0%), sendo este relaxamento potencializado pelo endotélio (Emax:88.1 ± 2.1%). A inibição da AC com MDL-12.330A (10 μM) ou da GCs com ODQ (1 μM), reduziram o relaxamento de 88,1 ± 2,1%, para 48,35 ± 3,01% e 19,95 ± 2,32%, respectivamente. A pré-contração com KCl 45 mM ou o tratamento das preparações com TEA (5 mM), reduziram quase que por completo o efeito relaxante do composto. A inibição da Ca2+/ATPase reticular com CPA (10 μM), reduziu o relaxamento estimulado pelo LQFM 021 em aproximadamente 66,5%. Curva concentração-resposta contrátil induzida pela fenilefrina (0,1 nM a 1 μM) ou pelo CaCl2 (0 a 3 mM, em meio zero-cálcio + fenilefrina) foram reduzidas pelo pré-tratamento das preparações com LQFM 021 (EC50). Em conclusão, este estudo mostrou que o novo derivado sintético de pirazol LQFM 021 é um possível inibidor de PDE-3 e possui atividade vasorelaxante. O endotélio participa e potencializa o relaxamento estimulado pelo composto. A via da GCs e AC estão envolvidas no mecanismo de ação do LQFM 021. Também foi evidenciada a participação do retículo sarcoplasmático, bem como o fluxo de K+ e de Ca2+ através da membrana celular

Development and validation and of spectrophotometrical analytical methodology for quantification of mebendazole raw material and oral suspension

v.6, n.1, p.25-32, jan./mar. 2009.Submitted by Marlene Santos ([email protected]) on 2013-09-17T17:37:17Z No. of bitstreams: 1 5858-22021-1-PB.pdf: 153875 bytes, checksum: b70d86c80d38b649d8b0377467856cb4 (MD5)Approved for entry into archive by Claudia Moura ([email protected]) on 2013-10-18T19:12:32Z (GMT) No. of bitstreams: 1 5858-22021-1-PB.pdf: 153875 bytes, checksum: b70d86c80d38b649d8b0377467856cb4 (MD5)Approved for entry into archive by Claudia Moura ([email protected]) on 2013-10-18T19:19:59Z (GMT) No. of bitstreams: 1 5858-22021-1-PB.pdf: 153875 bytes, checksum: b70d86c80d38b649d8b0377467856cb4 (MD5)Made available in DSpace on 2013-10-18T19:20:32Z (GMT). No. of bitstreams: 1 5858-22021-1-PB.pdf: 153875 bytes, checksum: b70d86c80d38b649d8b0377467856cb4 (MD5) Previous issue date: 2009-03Pró-Reitoria de Pesquisa e Pós-Graduação da Universidade Federal de Goiás.O mebendazol é um fármaco que atua como anti-helmíntico de amplo espectro de ação contra nematóides e cestóides. Entre as metodologias utilizadas para sua determinação, destaca-se a possibilidade de determinação quantitativa de mebendazol por meio de métodos espectrofotométricos, por apresentarem boa sensibilidade e ter custos mais acessíveis. O presente trabalho teve como objetivo desenvolver e validar uma metodologia analítica para determinação deste fármaco em matéria-prima e suspensão oral, utilizando a espectrofotometria de ultravioleta. O método mostrou ser simples, rápido, específico, linear, exato, preciso e robusto para ser executado na rotina de um laboratório de controle de qualidade, sendo uma alternativa aos métodos utilizados.The mebendazole is a drug that acts as anti-helminthic of broad spectrum of action against nematodes and cestodes. Among the methodologies used for their determination, highlights the possibility for quantitative determination of mebendazole is through methods spectrophotometrics, to have good sensitivity and have cost more accessible. This study aimed to develop and validate a method for analytical determination of mebendazole in raw material and in oral suspension, using the ultraviolet spectrophotometry. The method proved to be simple, rapid, specific, linear, accurate, precise and robust to run the routine of a laboratory of quality control, and is an alternative to methods used

Synthesis, docking studies, pharmacological activity and toxicity of a novel pyrazole derivative (LQFM 021) - possible effects on phosphodiesterase

Submitted by Liliane Ferreira ([email protected]) on 2018-08-23T13:40:13Z No. of bitstreams: 2 Artigo - Daniella Ramos Martins - 2013.pdf: 1568399 bytes, checksum: 5c6f84859e286fa8622ce63354ca2ed5 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Rejected by Luciana Ferreira ([email protected]), reason: Olhe a citação: MARTINS, Daniella Ramos et al. Synthesis, docking studies, pharmacological activity and toxicity of a novel pyrazole derivative (LQFM 021)-possible effects on phosphodiesterase. Chemical and Pharmaceutical Bulletin, Tokyo, v. 61, n. 5, p. 524-531, May, 2013. Não há vírgula depois do mês. on 2018-08-24T12:44:20Z (GMT)Submitted by Liliane Ferreira ([email protected]) on 2018-08-24T14:14:42Z No. of bitstreams: 2 license_rdf: 9 bytes, checksum: 42dd12a06de379d3ffa39b67dc9c7aff (MD5) Artigo - Daniella Ramos Martins - 2013.pdf: 1568399 bytes, checksum: 5c6f84859e286fa8622ce63354ca2ed5 (MD5)Approved for entry into archive by Luciana Ferreira ([email protected]) on 2018-08-27T11:23:32Z (GMT) No. of bitstreams: 2 license_rdf: 9 bytes, checksum: 42dd12a06de379d3ffa39b67dc9c7aff (MD5) Artigo - Daniella Ramos Martins - 2013.pdf: 1568399 bytes, checksum: 5c6f84859e286fa8622ce63354ca2ed5 (MD5)Made available in DSpace on 2018-08-27T11:23:32Z (GMT). No. of bitstreams: 2 license_rdf: 9 bytes, checksum: 42dd12a06de379d3ffa39b67dc9c7aff (MD5) Artigo - Daniella Ramos Martins - 2013.pdf: 1568399 bytes, checksum: 5c6f84859e286fa8622ce63354ca2ed5 (MD5) Previous issue date: 2013-05This study describes the synthetic route and molecular computational docking of LQFM 021, as well as examines its biological effects and toxicity. The docking studies revealed strong interaction of LQFM 021 to phosphodiesterase-3 (PDE-3). In isolated arteries, the presence of endothelium potentiates the relaxation for LQFM 021 and the inhibition cyclic nucleotides reduced the relaxation. Pre-contraction with KCl (45 mm), the treatment with tetraethylammonium (TEA) (5 mm) and inhibition of reticular Ca2+-ATPase showed an inhibitory effect on relaxation. Moreover, the compound reduced the contraction evoked by the Ca2+ influx. Acute toxicity tests revealed that the compound was practically nontoxic. In conclusion, this study showed that a new synthetic derivative of pyrazole is a possible PDE-3 inhibitor and has vasorelaxant activity and low toxicit